Dr. Zilbermint specializes in the diagnosis and treatment of metabolic and endocrine-related conditions.
10 CENTER DR Room 1-3216, MSC 1103
Bethesda Md 20892-1103
For FedEx use:
Bethesda Md 20892
Dr. Zilbermint is a board-certified Endocrinologist. He received his medical degree from the State Medical and Pharmaceutical University N. Testemitanu, Moldova. He completed his Internal Medicine training at Saint Agnes Hospital, Baltimore, MD. Zilbermint joined the Endocrinology Fellowship at National Institute of Health in July 2012.
During his work at the Section on Endocrinology and Genetics, NICHD, he developed a particular interest in rare genetic diseases. He was the first to describe and publish the clinical phenotype of the NIH cohort of patients with novel mutations in ARMC5 gene, which can cause macronodular adrenal hyperplasia and Cushing’s syndrome. Zilbermint was invited to share this discovery as an oral presentation at the International Congress of Endocrinology/ Endocrine Society’s 96th Annual Meeting in Chicago, IL in June 2014. He is currently interested in exploring whether the ARMC5 gene plays a role in other endocrinopathies.
Dr. Zilbermint is an associate clinical investigator in the following NIH clinical research studies: “A Clinical and Genetic Investigation of Pituitary Tumors and Related Hypothalamic Disorders”, “Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue”, and “Evaluation of Patients with Endocrine-Related Conditions”.
Dr. Zilbermint received awards and grants from European Society of Endocrinology, International Society of Endocrinology and Endocrine Society. He is an active volunteer at a camp for children with type I diabetes.
|Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.||Faucz FR,Zilbermint M,Lodish MB,Szarek E,Trivellin G,Sinaii N,Berthon A,Libé R,Assié G,Espiard S,Drougat L,Ragazzon B,Bertherat J,Stratakis CA||J Clin Endocrinol Metab||2014 Jun|
|A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical 'salt bridge' Kir3.4 residue.||Monticone S,Bandulik S,Stindl J,Zilbermint M,Dedov I,Mulatero P,Allgaeuer M,Richard Lee CC,Stratakis CA,Ann Williams T,Tiulpakov A||J Clin Endocrinol Metab||2014 Oct 16|
|Death in pediatric Cushing syndrome is uncommon but still occurs.||Gkourogianni A,Lodish MB,Zilbermint M,Lyssikatos C,Belyavskaya E,Keil MF,Stratakis CA||Eur J Pediatr||2014 Sep 23|
|Pituitary stalk lesion in a 13-year-old female.||Zilbermint M,Ramnitz MS,Lodish MB,Kanaka-Gantenbein C,Kattamis A,Lyssikatos C,Patronas NJ,Quezado MM,Stratakis CA||J Pediatr Endocrinol Metab||2014 Mar|
|Relationship between sex hormones and cognitive performance in men with substance use.||Zilbermint MF,Wisniewski AB,Xu X,Selnes OA,Dobs AS||Drug Alcohol Depend||2013 Mar 1|
|Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.||Zilbermint MF,Dobs AS||Future Oncol||2009 Oct|